Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma.
Saved in:
| Title: | Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. |
|---|---|
| Authors: | Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.; Department of Medicine, Medical School, Trinity College Dublin University, Dublin, Ireland., Meyer T; Department of Oncology, Royal Free Hospital, London, UK.; Department of Oncology, UCL Cancer Institute, University College London, London, UK., Do RKG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Light JS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sherrin S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yaqubie A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., O'Neill AC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Harding JJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., Al-Rajabi R; Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Denlinger CS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Cano P; Department of Hematology/Oncology, Sudbury Regional Hospital, Sudbury, ON, Canada., Cornelius AS; Department of Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI, USA., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., DiPrimeo D; Biometrics, Puma Biotechnology Inc., Los Angeles, CA, USA., Eli LD; Translational Medicine and Biometrics, Puma Biotechnology Inc., Los Angeles, CA, USA., Gordan JD; Division of Hematology/Oncology, CSF GI Medical Oncology, San Francisco, CA, USA., Solit DB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA. |
| Source: | Liver cancer [Liver Cancer] 2024 Aug 08; Vol. 14 (1), pp. 58-67. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40144471 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Abou-Alfa+GK%22">Abou-Alfa GK</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.; Department of Medicine, Medical School, Trinity College Dublin University, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Meyer+T%22">Meyer T</searchLink>; Department of Oncology, Royal Free Hospital, London, UK.; Department of Oncology, UCL Cancer Institute, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Do+RKG%22">Do RKG</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Light+JS%22">Light JS</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Sherrin+S%22">Sherrin S</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Yaqubie+A%22">Yaqubie A</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22O'Neill+AC%22">O'Neill AC</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Harding+JJ%22">Harding JJ</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Al-Rajabi+R%22">Al-Rajabi R</searchLink>; Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA.<br /><searchLink fieldCode="AU" term="%22Denlinger+CS%22">Denlinger CS</searchLink>; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Cano+P%22">Cano P</searchLink>; Department of Hematology/Oncology, Sudbury Regional Hospital, Sudbury, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Cornelius+AS%22">Cornelius AS</searchLink>; Department of Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.<br /><searchLink fieldCode="AU" term="%22O'Reilly+EM%22">O'Reilly EM</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22DiPrimeo+D%22">DiPrimeo D</searchLink>; Biometrics, Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Eli+LD%22">Eli LD</searchLink>; Translational Medicine and Biometrics, Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Gordan+JD%22">Gordan JD</searchLink>; Division of Hematology/Oncology, CSF GI Medical Oncology, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Solit+DB%22">Solit DB</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101597993%22">Liver cancer</searchLink> [Liver Cancer] 2024 Aug 08; Vol. 14 (1), pp. 58-67. <i>Date of Electronic Publication: </i>2024 Aug 08 (<i>Print Publication: </i>2025). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22S%2E+Karger%22">S. Karger </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101597993 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2235-1795 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216645553%22">16645553 </searchLink><i>NLM ISO Abbreviation: </i>Liver Cancer <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40144471 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1159/000540290 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 58 Titles: – TitleFull: Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Abou-Alfa GK – PersonEntity: Name: NameFull: Meyer T – PersonEntity: Name: NameFull: Do RKG – PersonEntity: Name: NameFull: Piha-Paul SA – PersonEntity: Name: NameFull: Light JS – PersonEntity: Name: NameFull: Sherrin S – PersonEntity: Name: NameFull: Yaqubie A – PersonEntity: Name: NameFull: O'Neill AC – PersonEntity: Name: NameFull: Harding JJ – PersonEntity: Name: NameFull: Al-Rajabi R – PersonEntity: Name: NameFull: Denlinger CS – PersonEntity: Name: NameFull: Cano P – PersonEntity: Name: NameFull: Cornelius AS – PersonEntity: Name: NameFull: O'Reilly EM – PersonEntity: Name: NameFull: DiPrimeo D – PersonEntity: Name: NameFull: Eli LD – PersonEntity: Name: NameFull: Gordan JD – PersonEntity: Name: NameFull: Solit DB IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 08 Text: 2024 Aug 08 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 2235-1795 Numbering: – Type: volume Value: 14 – Type: issue Value: 1 Titles: – TitleFull: Liver cancer Type: main |
| ResultId | 1 |